Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RAREthis companyUltragenyx Pharmaceutical Inc.	$15.98	-3.95×	-28.35×	3.37×	-6.56×	-2636.3%	83.8%	-79.5%	-85.4%	718.8%	-43.5%	-20.8%	-15.95×	-1.78×	-8.63×	2.48×	0.0%	2	-5.22	2	B-
ABEOAbeona Therapeutics Inc.	$2.48	3.93×	1.75×	47.95×	2.87×	-76.4%	73.7%	-1536.9%	1223.1%	44.7%	-44.0%	-30.2%	0.16×	-0.68×	-23.92×	6.93×	0.0%	2	-3.55	2	C
BBIOBridgeBio Pharma, Inc.	$75.34	-20.18×	-7.27×	30.05×	-25.49×	-271.4%	94.4%	-113.3%	-145.3%	35.1%	-108.5%	-3.0%	-1.31×	-3.19×	-10.72×	2.62×	0.0%	2	-0.07	2	C
BMRNBioMarin Pharmaceutical Inc.	$56.07	32.65×	1.87×	3.54×	18.73×	-87.5%	77.1%	16.6%	10.8%	5.7%	5.6%	6.4%	0.11×	-1.17×	48.95×	5.21×	0.0%	3	0.33	3	B
FDMT4D Molecular Therapeutics, Inc.	$12.43	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
MGTXMeiraGTx Holdings plc	$9.34	-5.6×	-110.38×	7.86×	-7.4×	-554.4%	94.0%	-130.2%	-140.3%	1971.4%	-70.9%	-7.8%	-15.31×	-0.25×	-8.69×	0.75×	0.0%	6	4.07	3	B
Peer median	—	-3.1×	0.86×	7.86×	-2.99×	-184.8%	91.1%	-130.2%	-140.3%	35.1%	-44.0%	-7.8%	0.04×	-0.68×	-8.69×	5.21×	0.0%	3	0.33	2	—